Genetic Use Restriction Technologies, Intellectual Property Rights and Sustainable Development in Eastern and Southern Africa
East African Law Journal (EALJ) · 27.08.2025 · 11-23
DOI: 10.66563/ealj.vi.3444 ↗Kurz gefasst
Fachartikel in der Zeitschrift East African Law Journal (EALJ), online erschienen am 27.08.2025. Verfasst von Patricia Kameri-Mbote Mbote und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This paper addresses the link between Intellectual Property Protection (IPP) and Genetic Use Restriction Technologies (GURTS). The central issue is the impact of IPP for GURTs innovations on access to seeds and technologies by farmers in developing countries. It focuses on Intellectual Property Rights (IPRs) considerations and other related regulatory aspects regarding the potential impact of GURTs in Eastern and Southern Africa (ESA). While both IPRs and GURTs allow control over the use of genetic materials, they differ in the mode of control. Thus, the question always is how the countries in the region can use regulatory mechanisms to harness the positive impacts of GURTs without compromising their national and regional sustainable development goals.
Zitieren
APA
Mbote, P. K., & Odek, J. O. (2025). Genetic Use Restriction Technologies, Intellectual Property Rights and Sustainable Development in Eastern and Southern Africa. East African Law Journal (EALJ), 11-23. https://doi.org/10.66563/ealj.vi.3444
Vancouver
Mbote PK, Odek JO. Genetic Use Restriction Technologies, Intellectual Property Rights and Sustainable Development in Eastern and Southern Africa. East African Law Journal (EALJ). 2025:11-23. doi:10.66563/ealj.vi.3444
BibTeX
@article{Mbote2025,
author = {Mbote, Patricia Kameri-Mbote and Odek, James Otieno-odek},
title = {Genetic Use Restriction Technologies, Intellectual Property Rights and Sustainable Development in Eastern and Southern Africa},
journal = {East African Law Journal (EALJ)},
year = {2025},
pages = {11--23},
doi = {10.66563/ealj.vi.3444}
}
EUVIMED